Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy

References

• WickhamRBest practice management of CINV in oncology patients: II. Antiemetic guidelines and rationale for useJ Support Oncol201082 Suppl 1101520629453
   PubMedGoogle Scholar
• de Boer-DennertMde WitRSchmitzPIPatient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonistsBr J Cancer1997768105510619376266
   PubMed Web of Science ®Google Scholar
• CarelleNPiottoEBellangerAGermanaudJThuillierAKhayatDChanging patient perceptions of the side effects of cancer chemotherapyCancer200295115516312115329
   PubMed Web of Science ®Google Scholar
• RussoSCinauseroMGerratanaLFactors affecting patient’s perception of anticancer treatments side-effects: an observational studyExpert Opin Drug Saf201413213915024073801
   PubMed Web of Science ®Google Scholar
• SunCCBodurkaDCWeaverCBRankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancerSupport Care Cancer200513421922715538640
   PubMed Web of Science ®Google Scholar
• GrunbergSMChemotherapy-induced nausea and vomiting incidence and prevalenceAm Soc Clin Oncol Educ Book20123254154324451792
   PubMedGoogle Scholar
• GrunbergSMDeusonRRMavrosPIncidence of chemotherapy-induced nausea and emesis after modern antiemeticsCancer2004100102261226815139073
   PubMed Web of Science ®Google Scholar
• CohenLde MoorCAEisenbergPMingEEHuHChemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settingsSupport Care Cancer200715549750317103197
   PubMed Web of Science ®Google Scholar
• HilariusDLKloegPHvan der WallEvan den HeuvelJJGundyCMAaronsonNKChemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based studySupport Care Cancer201220110711721258948
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): antiemesis. Version 12014Fort Washington, PA, USANational Comprehensive Cancer Network8192013 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed July 11, 2014
   Google Scholar
• FarrellCBrearleySGPillingMMolassiotisAThe impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of lifeSupport Care Cancer2013211596622610269
   PubMed Web of Science ®Google Scholar
• GrunbergSMWarrDGrallaRJEvaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – state of the artSupport Care Cancer201119 Suppl 1S43S4720972805
   PubMed Web of Science ®Google Scholar
• GrallaRJRoilaFTonatoMHerrstedtJMASCC/ESMO antiemetic guideline 2013 Available from: http://mascc.memberclicks.net/assets/documents/mascc_guidelines_english_2013.pdfAccessed September 6, 2013
   Google Scholar
• BaschEPrestrudAAHeskethPJAntiemetics: American Society of Clinical Oncology clinical practice guideline updateJ Clin Oncol201129314189419821947834
   PubMed Web of Science ®Google Scholar
• AaproMMolassiotisADicatoMThe effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)Ann Oncol20122381986199222396444
   PubMed Web of Science ®Google Scholar
• NavariRMManagement of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agentsDrugs201373324926223404093
   PubMed Web of Science ®Google Scholar
• HeskethPJComparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomitingCancer Invest200018216317310705879
   PubMed Web of Science ®Google Scholar
• RoilaFWarrDClark-SnowRADelayed emesis: moderately emetogenic chemotherapySupport Care Cancer200513210410815549426
   PubMed Web of Science ®Google Scholar
• GelingOEichlerHGShould 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implicationsJ Clin Oncol20052361289129415718327
   PubMed Web of Science ®Google Scholar
• HickokJTRoscoeJAMorrowGR5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trialLancet Oncol200561076577216198982
   PubMed Web of Science ®Google Scholar
• SaitoMAogiKSekineIPalonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trialLancet Oncol200910211512419135415
   PubMed Web of Science ®Google Scholar
• GrallaRLichinitserMVan der VegtSPalonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronAnn Oncol200314101570157714504060
   PubMed Web of Science ®Google Scholar
• EisenbergPFigueroa-VadilloJZamoraRImproved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetronCancer200398112473248214635083
   PubMed Web of Science ®Google Scholar
• AaproMGrunbergSManikhasGA phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapyAnn Oncol20061791441144916766588
   PubMed Web of Science ®Google Scholar
• HeskethPJGrunbergSMGrallaRJThe oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study GroupJ Clin Oncol200321224112411914559886
   PubMed Web of Science ®Google Scholar
• WarrDGHeskethPJGrallaRJEfficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapyJ Clin Oncol200523122822283015837996
   PubMed Web of Science ®Google Scholar
• WarrDGGrunbergSMGrallaRJThe oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trialsEur J Cancer20054191278128515939263
   PubMed Web of Science ®Google Scholar
• Dos SantosLVSouzaFHBrunettoATSasseADda Silveira Nogueira LimaJPNeurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic reviewJ Natl Cancer Inst2012104171280129222911671
   PubMedGoogle Scholar
• JordanKGrallaRJahnFMolassiotisAInternational antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practiceEur J Pharmacol201472219720224157984
   PubMed Web of Science ®Google Scholar
• GilmoreJWPeacockNWGuAAntiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE studyJ Oncol Pract2014101687424065402
   PubMedGoogle Scholar
• Bloechl-DaumBDeusonRRMavrosPHansenMHerrstedtJDelayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatmentJ Clin Oncol200624274472447816983116
   PubMed Web of Science ®Google Scholar
• HeskethPJVanBSAaproMDifferential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEur J Cancer20033981074108012736106
   PubMed Web of Science ®Google Scholar
• GrunbergSMObstacles to the implementation of antiemetic guidelinesJ Natl Compr Cancer Network200975601605
   Web of Science ®Google Scholar
• SalsmanJMGrunbergSMBeaumontJLCommunicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectivesJ Natl Compr Cancer Network2012102149157
   PubMed Web of Science ®Google Scholar
• CabanaMDRandCSPoweNRWhy don’t physicians follow clinical practice guidelines? A framework for improvementJAMA1999282151458146510535437
   PubMed Web of Science ®Google Scholar
• NavariRMPrevention of emesis from multiple-day and high-dose chemotherapy regimensJ Natl Compr Cancer Network2007515159
   Google Scholar
• EllebaekEHerrstedtJOptimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapyCurr Opin Support Palliat Care200821283418685391
   PubMedGoogle Scholar
• BremerKA single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. The Granisetron Study GroupEur J Cancer199228A6–7101810221320907
   PubMed Web of Science ®Google Scholar
• AaproMPiguetDGigerKThe antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days. The Granisetron Study GroupJ Cancer Res Clin Oncol199311995555598392077
   PubMed Web of Science ®Google Scholar
• RathUUpadhyayaBKArechavalaERole of ondansetron plus dexamethasone in fractionated chemotherapyOncology19935031681728459987
   PubMed Web of Science ®Google Scholar
• SledgeGWJrEinhornLNagyCHouseKPhase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapyCancer19927010252425281423181
   PubMed Web of Science ®Google Scholar
• FoxSMEinhornLHCoxEPowellNAbdyAOndansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapyJ Clin Oncol19931112239123958246028
   PubMed Web of Science ®Google Scholar
• HandbergJWesselVLarsenLHerrstedtJHansenHHRandomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapySupport Care Cancer19986163679458539
   PubMed Web of Science ®Google Scholar
• FauserAAPizzocaroGSchuellerJKhayatDWilkinsonPA double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomitingSupport Care Cancer200081495410650898
   PubMed Web of Science ®Google Scholar
• NobleABremerKGoedhalsLCupissolDDillySGA double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study GroupEur J Cancer199430A8108310887654434
   PubMed Web of Science ®Google Scholar
• ForniCFerrariSLoroLGranisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusionsSupport Care Cancer20008213113310739360
   PubMed Web of Science ®Google Scholar
• EinhornLHBramesMJDreicerRNicholsCRCullenMTJrBubaloJPalonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancerSupport Care Cancer200715111293130017436025
   PubMed Web of Science ®Google Scholar
• RozziANardoniCCoronaMPalonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II studySupport Care Cancer201119569770120467757
   PubMed Web of Science ®Google Scholar
• LorussoVGiampagliaMPetrucelliLSaracinoVPerroneTGnoniAAntiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapySupport Care Cancer201220123241324622534864
   PubMed Web of Science ®Google Scholar
• MussoMScaloneRBonannoVPalonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapySupport Care Cancer200917220520918839220
   PubMed Web of Science ®Google Scholar
• JordanKKinitzIVoigtWBehlendorfTWolfHHSchmollHJSafety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapyEur J Cancer20094571184118719135359
   PubMed Web of Science ®Google Scholar
• GaoHFLiangYZhouNNZhangDSWuHYAprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapyIntern Med J2013431737622141732
   PubMed Web of Science ®Google Scholar
• OlverINGrimisonPChatfieldMResults of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapySupport Care Cancer20132161561156823274926
   PubMed Web of Science ®Google Scholar
• HamadaSHinotsuSKawaiKAntiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapySupport Care Cancer20142282161216624652048
   PubMed Web of Science ®Google Scholar
• AlbanyCBramesMJFauselCJohnsonCSPicusJEinhornLHRandomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group StudyJ Clin Oncol201230323998400322915652
   PubMed Web of Science ®Google Scholar
• Aloxi^® (palonosetron HCl) injection [prescribing information]Woodcliff Lake, NJ, USAEisai Inc72013
   Google Scholar
• RojasCSlusherBSPharmacological mechanisms of 5-HT3 and tachykinin NK1 receptor antagonism to prevent chemotherapy-induced nausea and vomitingEur J Pharmacol20126841–31722425650
   PubMed Web of Science ®Google Scholar
• NavariRMPalonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonistExp Opin Drug Metab Toxicol200951215771586
   PubMed Web of Science ®Google Scholar
• RojasCStathisMThomasAGPalonosetron exhibits unique molecular interactions with the 5-HT3 receptorAnesth Analg2008107246947818633025
   PubMed Web of Science ®Google Scholar
• RojasCThomasAGAltJPalonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor functionEur J Pharmacol20106262–319319919836386
   PubMed Web of Science ®Google Scholar
• RojasCLiYZhangJThe antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivoJ Pharmacol Exp Ther2010335236236820724484
   PubMed Web of Science ®Google Scholar
• BotrelTEClarkOAClarkLPaladiniLFaleirosEPegorettiBEfficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysisSupport Care Cancer201119682383220495832
   PubMed Web of Science ®Google Scholar
• SchwartzbergLBarbourSYMorrowGRBallinariGThornMDCoxDPooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)Support Care Cancer201422246947724141698
   PubMed Web of Science ®Google Scholar
• JinYSunWGuDYangJXuZChenJComparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysisEur J Cancer Care20132214150
   Web of Science ®Google Scholar
• LikunZXiangJYiBXinDTaoZLA systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adultsOncologist201116220721621282670
   PubMed Web of Science ®Google Scholar
• YehYCBlouinGCReddyPEvidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomitingAm J Health Syst Pharm201471650050624589541
   PubMed Web of Science ®Google Scholar
• KolesarJMEickhoffJVermeulenLCSerotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?Am J Health Syst Pharm201471650751024589542
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPVan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• SalvoNBarnesEvan DraanenJProphylaxis and management of acute radiation-induced skin reactions: a systematic review of the literatureCurr Oncol20101749411220697521
   PubMed Web of Science ®Google Scholar
• SalvoNDobleBKhanLProphylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trialsInt J Radiat Oncol Biol Phys201282140841721075553
   PubMed Web of Science ®Google Scholar
• FeinbergBAGilmoreJHaislipSGondesenTSalehMNLenzWHData-driven medical decision-making in managing chemotherapy-induced nausea and vomitingCommunity Oncol200966267
   Google Scholar
• Tina ShihYCXuYEltingLSCosts of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapyCancer2007110367868517567835
   PubMed Web of Science ®Google Scholar
• BocciaRVGordanLNClarkGHowellJDGrunbergSMEfficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III studySupport Care Cancer201119101609161720835873
   PubMed Web of Science ®Google Scholar
• AffrontiMLSchneiderSMHerndonJEIISchlundtSFriedmanHSAdherence to antiemetic guidelines in patients with malignant glioma: translating evidence into practiceSupport Care Cancer20142271897190524570103
   PubMed Web of Science ®Google Scholar
• MolassiotisAFarrellCBourneKBrearleySGPillingMAn exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modelingJ Pain Symptom Manage201244569270322672920
   PubMed Web of Science ®Google Scholar
• NavariRMEinhornLHLoehrerPJSrA phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group studySupport Care Cancer200715111285129117375339
   PubMed Web of Science ®Google Scholar
• NavariRMGraySEKerrACOlanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trialJ Support Oncol20119518819522024310
   PubMedGoogle Scholar
• HowellJClarkGYellowleesAGutierrez-EsteinouREfficacy, safety, and tolerability of transdermal granisetron patch for prevention of multiday chemotherapy-induced nausea and vomiting: Phase III trial results (Abstract)J Oncol Pharm Pract200915Suppl 278
   Google Scholar